Financial news, mergers and acquisitions, partnerships, and alliances.
MyCartis said that the new company, Antelope Dx, is developing a home test to diagnose Chlamydia trachomatis and Neisseria gonorrhea.
The drug developer said that the biomarker panel will form the basis of a planned point-of-care test for acute respiratory distress syndrome.
MX3 Diagnostics' saliva test conducts electrochemical measurements of the ionic density of saliva to enable a quick response to dehydration concerns.
The system is designed to analyze data from routine blood and biochemistry tests to identify immunological abnormalities that indicate high cancer risk.
Trinity Biotech said that the decline in point-of-care revenues reflects lower sales in its two key geographic markets, Africa and the US.
